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ABSTRACT 
Objective: Owing to the difficulty in providing drug therapies against Methicillin-resistant Staphylococcus aureus (MRSA), the development of an 
effective and promising vaccine is an immense challenge in combatingMRSA infections. The present work focuses on the development of a peptide-
based vaccine, by identifying the epitopes from SPA antigen.  
Methods: The epitopes were identified based on different properties, such that they are capable of eliciting broadly neutralizing immune responses. 
The identified epitopes were subjected for peptide docking using Glide and antibody-antigen docking using ClusPro.  
Results: By in silico approach two epitopes “NLNEEQRNG” and “LKDDPSQSAN” were identified for SPA protein with sequence lengths of nine and 
ten respectively. The least energy for the peptide docking was observed for NLNEEQRNG sequence and the amino acid residues of this peptide share 
similar interaction with antibody-antigen docking. 
Conclusion: Based on the properties and docking studies the best-ranked epitope sequence is ‘NLNEEQRNG’. Further studies on this peptide 
sequence might be helpful for alternative therapy of MRSA infections. 
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INTRODUCTION 
Staphylococcus aureus infections are commonly known as Staph 
infections, which causes many diseases, in some cases leading to 
life-threatening conditions. The infections caused are resistant to 
antibiotics and are known asMethicillin-resistant Staphylococcus 
aureus (MRSA). Bacteremia incidence by Staph ranges between 
20-50 persons among 100,000 populations annually, of which 
approximately 10-30% patients die [1]. The staph infections are 
most commonly spread either by infections HA-MRSA (hospital 
acquired) or nosocomial MRSA and CA-MRSA (community 
acquired). There are multiple factors involved in influencing the 
outcomes of staph infections, but these infections are most 
commonly observed in infants and old. The methicillin, oxacillin, 
vancomycin-like antibiotics are resistant to staph which provides 
an immense challenge for developing new therapeutics to combat 
staph infections. 
The best way for combating the infections is via vaccination process, 
as vaccines elicit the immune response and provide humoral 
immunity. Vaccine technology mainly relies on the antigen that has 
the ability to boost the immune system. About 20 different antigens 
were evaluated clinically accounting for 19 different vaccines from S. 
aureus [2]. Although the vaccine studies were successful in animals 
and in preclinical toxicity studies, they were insufficient in providing 
an immune response in humans. Hence, many of the vaccine 
developments couldn’t advance phase 2 trials, and to date, there are 
no available vaccines against staph infections. The antigens in the 
study mostly included surface proteins and a class of microbial 
surface components recognizing adhesive matrix molecules 
(MSCRAMM). One of the antigen that was not yet studied from this 
class is Peptidoglycan-binding Lysm protein or also known as 
Staphylococcus aureus Protein A (SPA) or IgG binding protein.  
The MSCRAMM account for about 20 potential antigens that are 
anchored to peptidoglycan layer by sortase enzyme [3]. MSCRAMMs 
are essentially important in anchoring the desquamated epithelial 
cells of human and help in colonization. The clumping factor B bind 
to the fibrinogen of human [4]and other proteins SdrC/D, SasG/Pls, 
IsdA help in colonization on the surface of epithelial cells. Whereas 
the SPA binds to Fab region of antibody IgG [5] and activates the 
immune response of host leading to the disruption of cell mediated 
by classical and alternative pathways as depicted in fig. 1. The SPA 
has the capability of binding Fab region of the B-cell and inducing 
the programmed cell death process and hence is also known as B-
cell superantigen [6]. In addition SPA even function as binding to Fc 
region [7], which prevents normal phagocytosis process. In in vitro 
conditions, it is probably known that SPA binding inhibits the 
opsonophagocytosis [8]. All these works indicate that the SPA is 
potent in altering the immune responses of the host.  
Thus, we have focused on the B-cell superantigen SPA for the 
present study, as it is potent for developing a vaccine. In the early 
ages of vaccine development, the vaccines were developed by either 
attenuated or killed pathogens. But the present advancement in 
vaccine technology has proposed new targets for vaccines which 
include synthetic peptides that comprehend B-cell and T-cell 
epitopes [9]. The most important features concerned with the use of 
peptide-based vaccines rather than pathogen as whole include the 
following, they uniquely target on specified epitopes; they are even 
capable of skipping of immune evasion, non-protective responses, 
and autoimmunity. Furthermore, peptide-based vaccines can safely 
induce tolerance to specific allergens [10]. The accessibility of 
advanced computational algorithms and immunoinformatics 
databases with experimental validations helps in developing the 
antigen-specific peptide-based vaccines [9]. In this study, we have 
applied immunoinformatics tools for identifying the epitopes and 
molecular docking for predicting the best epitope. Identifying the 
potential epitope will help in developing a peptide-based vaccine, 
which could certainly be one of the best approaches in the 
alternative treatment of staph infections. 
MATERIALS AND METHODS 
The main objective of immunoinformatics studies on SPA is to 
identify the epitopes that can mount an immune response against 
staph infections. This study could cater a most promising alternative 
in combating infections than that of conventional methods.  
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Protein sequence retrieval 
The protein sequence of SPA was retrieved from the National Centre 
for Biotechnology Information (NCBI) database with ID: A0A0E8ISN 
[12]. NCBI is a database that hosts the information related to 
sequences of protein, DNA and RNA which are known as RefSeq 
(Reference Sequence). The data are mined taxonomically, being 
non-redundant and that which are highly annotated.  
The data set hosted by NCBI are continuously shared with other 
data hosting servers like European Nucleotide Archive and the 
DNA Database of Japan via INSDC (International Nucleotide 
Sequence Database Collaboration) [13]. 
 
 
Fig. 1: Staphylococcus aureus cell components and its adhesion on disrupted human epithelial cells (source: William et al., 2015 [11]) 
 
Protein domain prediction  
InterPro is a repository for protein related information like domain 
architecture, motifs, Gene Ontologies, etc. which are known as 
signatures. These signatures are integrated from eleven different 
sources viz., ProDom, PRINTS, PROSITE, Pfam, CATH-Gene3D, SMART, 
TIGRFAM, HAMAP, PIRSF and PANTHER. With the different signatures 
integrated into InterPro database, it provides a hub to predict domains, 
motifs, etc. via its search system InterProScan. Hence, protein domains 
for SPA antigen were predicted by InterProScan [14].  
Epitopes prediction 
Epitopes for SPA antigen were predicted by considering the 
properties of amino acid residues through available online web 
servers. The immune epitope database (IEDB) analysis resource 
system [15] was used to predict the epitopes by six different 
parameters. Six parameters applied here includes antigenicity, B-cell 
linear epitopes, surface accessibility, the number of beta turns, 
flexible residues, and hydrophilicity. The antigenic peptides were 
predicted by applying Kolaskar and Tongaonkar [16] antigenicity 
scale (threshold=1.00). It integrates the semi-empirical approach 
and uses physicochemical properties of amino acids for predictions. 
The hidden markov models and propensity scales were applied to 
identify the linear epitopes of B-Cell by Bepipred [17] 
(threshold=0.350). The Emini surface accessibility scale [18] was 
used in order to identify the residues that are accessible to solvent. 
The surface accessibility is calculated by the formula Sn = 
(i−1Π6δn+4+i) × (0.37)−6
Peptide docking 
, and when Sn value for hexapeptide is 
greater than 1 indicates the probability of surface accessible 
residues. The beta turns are predicted by Chou and Fasman [19]a 
semi-empirical method which takes into account the relative 
frequencies of amino acids. Karplus and Schulz scale [20] of 
flexibility (threshold=1) were applied predicting the flexible 
residues and this algorithm uses the knowledge of 31 proteins 
whose B-factor temperatures are derived. Hydrophobic and polar 
nature of amino acids were predicted by Parker Hydrophilicity 
Prediction [21] and the predictions by this scale relies on the 
experimental calculation of the retention time of a peptide while 
high-performance liquid chromatography (HPLC).  
The predicted epitopes were then subjected to peptide docking 
against human IgG protein (antibody). The peptide docking was 
performed using the peptide docking panel from Bioluminate 
module [22] of Schrodinger. In this panel, the grid for the antibody is 
specified by selecting the binding site residues, and the peptide 
sequence is uploaded. The grid calculations are performed by Glide 
[23] and the peptide is modeled by MacroModel and conformations are 
generated by ConfGen [24]. Prior to setting up docking, the antibody was 
prepared by subjecting it to a protein preparation wizard. The docking 
was performed by SP-peptide approach from a glide, and the poses were 
then scored by MMGBSA (Molecular Mechanics, the Generalized Born 
model, and Solvent Accessibility) [25].  
Antibody-antigen docking 
To interpret that the epitopes predicted are potentially capable of 
binding to the antibody, we have considered the protein structure of 
SPA. The PDB search for the SPA antigen has retrieved the partial 
structure of the protein, which includes two chains of IgG binding 
domain. The availability of 3D structure of antigen, we subjected IgG 
and SPA to ClusPro [26] and was set to antibody-antigen docking. 
The additional parameters like binding site amino acids were 
provided. ClusPro is a web server that provides a bench for different 
macromolecular dockings, like protein-protein, antibody-antigen, 
multimer docking, etc. ClusPro at its back end uses PIPER program 
which applies Fast Fourier Transform (FFT) correlation function 
with structure-based pairwise intermolecular potentials Decoys As 
the Reference State (DARS) [27]. The docking interactions were 
analyzed using Bioluminate module of Schrodinger and visualized 
by Chimera. Further, the binding residues of epitopes by peptide 
docking and SPA by antibody-antigen docking were compared, to 
predict the potential epitope. 
RESULTS  
The potential epitopes that can elicit the immune responses were 
predicted by B-Cell epitope prediction tool IEDB. We have employed 
about six different algorithms for the computational screening of 
epitopes in SPA antigen. All these algorithms predicted epitopes are 
spanning in different regions; the best-scored epitopes were 
selected. The domain analysis of SPA antigen has indicated to have 
five domains (table 1). The epitopes that could score well when all 
the six scale are considered were selected as potential epitopes. A 
continuous stretch of 100 residues from 330-420 amino acids has 
observed to be an epitope by all the scales, excluding the antigenicity 
property and lacks IgG binding domain. This region is made up of an 
octapeptide repeat whose function is not yet known and hence was 
discarded for further study. The regions that were found to be 
potential when all the scales considered were spanning in 
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between 80-100, 174-182, 187-196and 460-480 (fig. 2). The 
other setback was found with the peptide sequence region 460-
480 as it is not the part of IgG binding domain and was also 
discarded in docking studies. When compared to the peptide 
sequences of 174-182 and 187-196 the peptide region of 80-100 
have shown low levels of antigenicity. Hence, the final peptide 
sequences considered as epitopes were 174-182 and 187-196 
(table 2). 
 
Table 1: Domain analysis of SPA antigen 
S. No. Domains Region Function 
1. YSIRK Signaling Peptide 1-40 Substrate recognition 
2. IgG binding domain 41-330 Capable of binding Fab and Fc region of IgG antibody 
3. Octapeptide 331-420 Unknown 
4. LysM (lysine motif) domain 421-460 Peptidoglycan binding 
5. LPXTG domain 461-517 Cell wall anchoring 
The table shows major portion of antigen constitutes of five repeats of IgG domain. 
 
 
Fig. 2: Epitope prediction of SPA 
 
Table 2: The best potential epitopes predicted 
S. No. Peptide sequence Region 
1. NLNEEQRNG 174-182 
2. LKDDPSQSAN 187-196 
 
The table 2 shows potential epitopes predicted based on the 
domains and considering different parameters like antigenicity, 
linear epitope, beta turns, hydrophilicity, surface accessibility and 
flexibility. 
These predicted epitopes were subjected to peptide docking against 
the human IgG protein (PDB: 1HZH [28]). To the antibody, the grid 
box was prepared on one light chain (L) and one heavy chain (H). 
The peptide sequences were uploaded to peptide dock panel and 
were subjected sequential 3D generation of peptides followed by 
docking. The generated peptides were sequentially docked to the 
established grid of antibody and different poses were generated for 
each peptide. These poses were then scored on the basis of the 
MMGBSA, and the best-scored poses are given in table 3. The 
binding interactions of peptide and antibody were analyzed by 
protein-protein interaction analysis wizard (table 4). The 
intermolecular interactions between the peptide and antibody are 
non-covalent hydrogen bonds. The common interacting residues of 
the antibody with two peptides are Ser 94 and Glu 1 of the light 
chain (L) (fig. 3,4).  
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Table 3: Docking scores of best poses 
S. No. Peptide sequence Docking score Glide score Prime energy MMGBSA 
1. NLNEEQRNG -5.278 -5.278 -54817.9 -70.60 
2. LKDDPSQSAN -5.204 -5.204 -53831.2 -69.16 
The table shows best pose for the two peptides based on MMGBSA and socking scores.  
 
Table 4: Antibody-peptide interaction analysis 
S. No. Protein (Antibody) Peptide (Epitope) Interacting residues Distance Type of interaction 
Protein Peptide 
1. IgG-human NLNEEQRNG L: Ser 30 X: Asn 3 2.7 Hydrogen bond 
L: Ser 94 X: Arg 7  3.2 Hydrogen bond 
L: Glu 1 X: Asn 8 2.9 Hydrogen bond 
H: Ala 61 X: Gly 9 2.8 Hydrogen bond 
2. IgG-human LKDDPSQSAN L: Ser 95 X: Asp 4 2.8 Hydrogen bond 
L: Ser 94 X: Ser 6 2.7 Hydrogen bond 
L: Glu 1 X: Gln 7 2.8 Hydrogen bond 
H: Phe 45 X: Asn 10 2.9 Hydrogen bond 
The table shows interactions between antibody and antigen were analyzed, indicating most of the interactions to be non-covalent hydrogen bonds. 
 
 
Fig. 3: Peptide docking interaction analysis of NLNEEQRNG 
against IgG 
 
Heavy chains of IgG are represented in green and light chains in blue 
whereas epitope in brick red color 
 
 
Fig. 4: Peptide docking interaction analysis of LKDDPSQSAN 
against IgG 
 
Heavy chains of IgG are represented in green and light chains in blue 
whereas epitope in brick red color 
To identify the potential epitope we have then considered the 
experimental 3D structure of the SPA antigen(PDB: 4NPF) [29]and 
subjected to antibody-antigen docking. The 3D structure of the 
protein 4NPF constitute of two chains belonging to the IgG domain. 
The sequence of 4NPF was manually observed and the epitopes 
were found on both the chains spanning between residues 22-28 
(NLNEEQRNG) and 33-43 (LKDDPSQSAN) and hence only one chain 
was selected. The docking was performed using ClusPro using 
antibody mode. A cluster of 20 poses was generated with the similar 
kind of interaction. Of the cluster, the lowest energy pose-425.3 
Kcal/mol was analyzed using protein interaction analysis wizard 
(table 5). Similarly, to peptide docking the antibody-antigen docking 
also show non-covalent hydrogen bonds between the interacting 
residues (fig. 5). The antigen interaction residues are similar to that 
of the peptide sequence NLNEEQRNG. The results here indicate that 
the NLNEEQRNG to be one of the potential epitope and the further 




Fig. 5: Antibody-antigen docking interactions 
 
Heavy chains of IgG are represented in green and light chains in blue 
whereas antigen in brick red color 
 
Table 5: Antibody-peptide interaction analysis 
S. No. Interacting Residues Distance Type of interaction 
Antibody (1HZH) Antigen (4NPF) 
1. L: Ser 94 X: Arg 27 2.9 Hydrogen bond 
L: Glu 1  X: Asn 28 3.1 Hydrogen bond 
H: Ala 61 X: Gly 29 3.4 Hydrogen bond 
The table shows interactions between antibody and antigen were analyzed, indicating most of the interactions to be non-covalent hydrogen bonds. 
 
DISCUSSION 
The identification of epitopes on the surface of antigens can be 
widely used in diagnostics and mainly in designing the peptide 
vaccines[30]. We have selected an IgG binding antigen for 
identification of epitopes which can elicit B-cell responses, as the 
identification of B-cell epitopes has been attracted by several 
scientists for developing promising vaccines [31]. The most vital 
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process in epitope-based vaccine design is a prediction of epitopes 
and mapping them on the surface of the antigen. In the present 
study, we have applied basic physicochemical properties of amino 
acids as parameters for predicting the epitopes. 
The antigenicity scale was used to determine the antigenic sites as 
they can bind to the antibody and are capable of eliciting the 
immune responses [32]. We have identified the linear B-cell 
epitopes despite many of the B-cell epitopes are conformational 
because linear epitopes are easier to identify and synthesize[33]. In 
predictions, the hydrophobic scale and surface accessibility are 
considered as the preferable interaction of amino acids occur within 
hydrophobic residues and those which are solvent accessible [34]. 
Further, it is known that the epitopes are present in between the 
turns of two parallel arranged beta sheets [35] and hence were 
predicted. The flexibility of peptides was also predicted as they are 
important in attaining the secondary structure and allows the 
segmental motion in antigenic site to bind the antibody [36]. 
Two peptide sequences (table 2) were found to be potentially 
obeying all these parameters indicating that they might influence in 
eliciting the immune responses. The potency of predicted epitopes 
was analyzed by molecular docking strategies. To avoid the blind 
dock, the grid was prepared on the antibody by selecting one light 
chain and heavy as they serve as the binding sites for the antigen. 
The peptide docking results indicate that the peptide 
NLNEEQRNGserve as the potent epitopes than that of 
LKDDPSQSANas it has the least binding energy, dock score 
andMMGBSA score (table 3). Further to understand the best among 
them the experimental structure of the antigen (4NPF) was 
considered. The SPA protein has five small three-helix-bundle 
domains which are linked by flexible linkers [29]. The complete 
crystal structure of SPA is not available, the only experimental 
structure of SPA is PDB: 4NPF. This structure has two repeats of IgG 
binding domain as two chains. The antibody-antigen docking was 
carried out to understand the actual interacting residues. This 
analysis has indicated that the amino acid residues Arg 27, Asn 28, 
Gly29 were found to be interacting with the antibody (table 5). 
These residues are similar from the tail end of the peptide sequence 
NLNEEQRNG. These studies indicate that peptide sequence 
NLNEEQRNG as a potential epitope and further studies on it may 
lead to the development of an alternative treatment against the 
staph infections. 
CONCLUSION 
The present study was focused on the identification of potential B-
cell epitope by immunoinformatics and molecular docking strategies 
against the SPA antigen. Two epitopes from the sequence of antigen 
were identified by six different basic physicochemical parameters. 
The docking studies suggest that the peptide sequence NLNEEQRNG 
of length nine residues may serve as the potent epitope in 
synthesizing a synthetic peptide vaccine. The current finding may 
further help the scientific communities and pharmacologists in 
developing a potent vaccine against staph infections. 
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